
Global Nuclear Medicine & Radiopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Nuclear Medicine & Radiopharmaceuticals market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Nuclear Medicine & Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Nuclear Medicine & Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Nuclear Medicine & Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Nuclear Medicine & Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Nuclear Medicine & Radiopharmaceuticals include Aurobindo Pharma, Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, Mundipharma and SIEMENS, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Nuclear Medicine & Radiopharmaceuticals, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Nuclear Medicine & Radiopharmaceuticals, also provides the sales of main regions and countries. Of the upcoming market potential for Nuclear Medicine & Radiopharmaceuticals, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nuclear Medicine & Radiopharmaceuticals sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Nuclear Medicine & Radiopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Nuclear Medicine & Radiopharmaceuticals sales, projected growth trends, production technology, application and end-user industry.
Nuclear Medicine & Radiopharmaceuticals Segment by Company
Aurobindo Pharma
Bracco Imaging
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
Mundipharma
SIEMENS
Bayer
Dongcheng
Eli Lilly
Novartis
China Isotope & Radiation
Nuclear Medicine & Radiopharmaceuticals Segment by Type
Diagnostic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals
Nuclear Medicine & Radiopharmaceuticals Segment by Application
Oncology
Cardiology
Thyroid
Others
Nuclear Medicine & Radiopharmaceuticals Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine & Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine & Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine & Radiopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Nuclear Medicine & Radiopharmaceuticals market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nuclear Medicine & Radiopharmaceuticals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Nuclear Medicine & Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Nuclear Medicine & Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Nuclear Medicine & Radiopharmaceuticals market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Nuclear Medicine & Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Nuclear Medicine & Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Nuclear Medicine & Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Nuclear Medicine & Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Nuclear Medicine & Radiopharmaceuticals include Aurobindo Pharma, Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, Mundipharma and SIEMENS, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Nuclear Medicine & Radiopharmaceuticals, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Nuclear Medicine & Radiopharmaceuticals, also provides the sales of main regions and countries. Of the upcoming market potential for Nuclear Medicine & Radiopharmaceuticals, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nuclear Medicine & Radiopharmaceuticals sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Nuclear Medicine & Radiopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Nuclear Medicine & Radiopharmaceuticals sales, projected growth trends, production technology, application and end-user industry.
Nuclear Medicine & Radiopharmaceuticals Segment by Company
Aurobindo Pharma
Bracco Imaging
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
Mundipharma
SIEMENS
Bayer
Dongcheng
Eli Lilly
Novartis
China Isotope & Radiation
Nuclear Medicine & Radiopharmaceuticals Segment by Type
Diagnostic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals
Nuclear Medicine & Radiopharmaceuticals Segment by Application
Oncology
Cardiology
Thyroid
Others
Nuclear Medicine & Radiopharmaceuticals Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine & Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine & Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine & Radiopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Nuclear Medicine & Radiopharmaceuticals market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nuclear Medicine & Radiopharmaceuticals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Nuclear Medicine & Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Nuclear Medicine & Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
198 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Nuclear Medicine & Radiopharmaceuticals Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Nuclear Medicine & Radiopharmaceuticals Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Nuclear Medicine & Radiopharmaceuticals Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Nuclear Medicine & Radiopharmaceuticals Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Nuclear Medicine & Radiopharmaceuticals Market Dynamics
- 2.1 Nuclear Medicine & Radiopharmaceuticals Industry Trends
- 2.2 Nuclear Medicine & Radiopharmaceuticals Industry Drivers
- 2.3 Nuclear Medicine & Radiopharmaceuticals Industry Opportunities and Challenges
- 2.4 Nuclear Medicine & Radiopharmaceuticals Industry Restraints
- 3 Nuclear Medicine & Radiopharmaceuticals Market by Manufacturers
- 3.1 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Manufacturers (2020-2025)
- 3.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Manufacturers (2020-2025)
- 3.3 Global Nuclear Medicine & Radiopharmaceuticals Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Nuclear Medicine & Radiopharmaceuticals Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Nuclear Medicine & Radiopharmaceuticals Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Nuclear Medicine & Radiopharmaceuticals Manufacturers, Product Type & Application
- 3.7 Global Nuclear Medicine & Radiopharmaceuticals Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Nuclear Medicine & Radiopharmaceuticals Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Nuclear Medicine & Radiopharmaceuticals Players Market Share by Revenue in 2024
- 3.8.3 2024 Nuclear Medicine & Radiopharmaceuticals Tier 1, Tier 2, and Tier 3
- 4 Nuclear Medicine & Radiopharmaceuticals Market by Type
- 4.1 Nuclear Medicine & Radiopharmaceuticals Type Introduction
- 4.1.1 Diagnostic Radiopharmaceuticals
- 4.1.2 Therapeutic Radiopharmaceuticals
- 4.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Type
- 4.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Type (2020-2031)
- 4.2.3 Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Type (2020-2031)
- 4.3 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Type
- 4.3.1 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Type (2020-2031)
- 4.3.3 Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Type (2020-2031)
- 5 Nuclear Medicine & Radiopharmaceuticals Market by Application
- 5.1 Nuclear Medicine & Radiopharmaceuticals Application Introduction
- 5.1.1 Oncology
- 5.1.2 Cardiology
- 5.1.3 Thyroid
- 5.1.4 Others
- 5.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Application
- 5.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Application (2020-2031)
- 5.2.3 Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Application (2020-2031)
- 5.3 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Application
- 5.3.1 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Application (2020-2031)
- 5.3.3 Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Application (2020-2031)
- 6 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region
- 6.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region (2020-2031)
- 6.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region (2020-2025)
- 6.2.2 Global Nuclear Medicine & Radiopharmaceuticals Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Nuclear Medicine & Radiopharmaceuticals Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Nuclear Medicine & Radiopharmaceuticals Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Nuclear Medicine & Radiopharmaceuticals Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Nuclear Medicine & Radiopharmaceuticals Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Nuclear Medicine & Radiopharmaceuticals Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Nuclear Medicine & Radiopharmaceuticals Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region
- 7.1 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region
- 7.1.1 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region (2020-2025)
- 7.1.3 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region (2026-2031)
- 7.1.4 Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Nuclear Medicine & Radiopharmaceuticals Revenue (2020-2031)
- 7.2.2 North America Nuclear Medicine & Radiopharmaceuticals Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Nuclear Medicine & Radiopharmaceuticals Revenue (2020-2031)
- 7.3.2 Europe Nuclear Medicine & Radiopharmaceuticals Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Nuclear Medicine & Radiopharmaceuticals Revenue (2020-2031)
- 7.4.2 Asia-Pacific Nuclear Medicine & Radiopharmaceuticals Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Aurobindo Pharma
- 8.1.1 Aurobindo Pharma Comapny Information
- 8.1.2 Aurobindo Pharma Business Overview
- 8.1.3 Aurobindo Pharma Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Aurobindo Pharma Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.1.5 Aurobindo Pharma Recent Developments
- 8.2 Bracco Imaging
- 8.2.1 Bracco Imaging Comapny Information
- 8.2.2 Bracco Imaging Business Overview
- 8.2.3 Bracco Imaging Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Bracco Imaging Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.2.5 Bracco Imaging Recent Developments
- 8.3 Cardinal Health
- 8.3.1 Cardinal Health Comapny Information
- 8.3.2 Cardinal Health Business Overview
- 8.3.3 Cardinal Health Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Cardinal Health Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.3.5 Cardinal Health Recent Developments
- 8.4 Curium Pharma
- 8.4.1 Curium Pharma Comapny Information
- 8.4.2 Curium Pharma Business Overview
- 8.4.3 Curium Pharma Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Curium Pharma Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.4.5 Curium Pharma Recent Developments
- 8.5 GE Healthcare
- 8.5.1 GE Healthcare Comapny Information
- 8.5.2 GE Healthcare Business Overview
- 8.5.3 GE Healthcare Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 GE Healthcare Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.5.5 GE Healthcare Recent Developments
- 8.6 Jubilant Pharma
- 8.6.1 Jubilant Pharma Comapny Information
- 8.6.2 Jubilant Pharma Business Overview
- 8.6.3 Jubilant Pharma Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Jubilant Pharma Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.6.5 Jubilant Pharma Recent Developments
- 8.7 Lantheus
- 8.7.1 Lantheus Comapny Information
- 8.7.2 Lantheus Business Overview
- 8.7.3 Lantheus Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 Lantheus Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.7.5 Lantheus Recent Developments
- 8.8 Mundipharma
- 8.8.1 Mundipharma Comapny Information
- 8.8.2 Mundipharma Business Overview
- 8.8.3 Mundipharma Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.8.4 Mundipharma Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.8.5 Mundipharma Recent Developments
- 8.9 SIEMENS
- 8.9.1 SIEMENS Comapny Information
- 8.9.2 SIEMENS Business Overview
- 8.9.3 SIEMENS Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.9.4 SIEMENS Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.9.5 SIEMENS Recent Developments
- 8.10 Bayer
- 8.10.1 Bayer Comapny Information
- 8.10.2 Bayer Business Overview
- 8.10.3 Bayer Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.10.4 Bayer Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.10.5 Bayer Recent Developments
- 8.11 Dongcheng
- 8.11.1 Dongcheng Comapny Information
- 8.11.2 Dongcheng Business Overview
- 8.11.3 Dongcheng Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.11.4 Dongcheng Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.11.5 Dongcheng Recent Developments
- 8.12 Eli Lilly
- 8.12.1 Eli Lilly Comapny Information
- 8.12.2 Eli Lilly Business Overview
- 8.12.3 Eli Lilly Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.12.4 Eli Lilly Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.12.5 Eli Lilly Recent Developments
- 8.13 Novartis
- 8.13.1 Novartis Comapny Information
- 8.13.2 Novartis Business Overview
- 8.13.3 Novartis Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.13.4 Novartis Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.13.5 Novartis Recent Developments
- 8.14 China Isotope & Radiation
- 8.14.1 China Isotope & Radiation Comapny Information
- 8.14.2 China Isotope & Radiation Business Overview
- 8.14.3 China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.14.4 China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.14.5 China Isotope & Radiation Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Nuclear Medicine & Radiopharmaceuticals Value Chain Analysis
- 9.1.1 Nuclear Medicine & Radiopharmaceuticals Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Nuclear Medicine & Radiopharmaceuticals Production Mode & Process
- 9.2 Nuclear Medicine & Radiopharmaceuticals Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Nuclear Medicine & Radiopharmaceuticals Distributors
- 9.2.3 Nuclear Medicine & Radiopharmaceuticals Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.